Phase three trial compares empasiprubart and immunoglobulin effects in CIDP, indicating treatment options.
EMVIGORATE will compare intravenous (IV) empasiprubart and IV immunoglobulin (IVIg) in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
No takes yet. Share an insight, caveat, or question.
Rinaldi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: